Orgenesis (NASDAQ:ORGS – Get Free Report) and Galecto (NASDAQ:GLTO – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, valuation, earnings, risk and analyst recommendations.
Risk & Volatility
Orgenesis has a beta of 1.32, suggesting that its stock price is 32% more volatile than the S&P 500. Comparatively, Galecto has a beta of 1.24, suggesting that its stock price is 24% more volatile than the S&P 500.
Analyst Ratings
This is a breakdown of recent ratings and recommmendations for Orgenesis and Galecto, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Orgenesis | 0 | 0 | 0 | 0 | 0.00 |
| Galecto | 0 | 0 | 1 | 0 | 3.00 |
Valuation & Earnings
This table compares Orgenesis and Galecto”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Orgenesis | $530,000.00 | 10.60 | -$55.36 million | N/A | N/A |
| Galecto | N/A | N/A | -$38.35 million | ($19.14) | -0.28 |
Galecto has lower revenue, but higher earnings than Orgenesis.
Institutional & Insider Ownership
22.6% of Orgenesis shares are owned by institutional investors. Comparatively, 14.2% of Galecto shares are owned by institutional investors. 5.7% of Orgenesis shares are owned by company insiders. Comparatively, 11.9% of Galecto shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Profitability
This table compares Orgenesis and Galecto’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Orgenesis | -3,827.81% | N/A | -130.18% |
| Galecto | N/A | -76.96% | -66.59% |
Summary
Galecto beats Orgenesis on 7 of the 11 factors compared between the two stocks.
About Orgenesis
Orgenesis Inc., a biotech company, focuses on cell and gene therapies worldwide. It operates through two segments, Octomera and Therapies. The company develops a Point of Care (POCare) platform that includes a pipeline of licensed cell based POCare therapies that are processed and produced under closed and automated POCare technology systems across a collaborative POCare network consisting of research institutes and hospitals. Its therapies include autologous; cell-based immunotherapies; and therapeutics for metabolic diseases, anti-viral diseases, and tissue regeneration. The company also provides development services, including regulatory services, pre-clinical studies, intellectual property services, and GMP process translation, as well as support services; hospital services; cell process development services; and distributed cell processing services. The company was formerly known as Business Outsourcing Service, Inc. and changed its name to Orgenesis Inc. in August 2011. Orgenesis Inc. was incorporated in 2008 and is headquartered in Germantown, Maryland.
About Galecto
Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB2064, a selective oral small molecule inhibitor of LOXL2 that is in Phase 2a clinical trial for the treatment of fibrotic diseases, including cancer and myelofibrosis; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis. Galecto, Inc. was founded in 2011 and is headquartered in Copenhagen, Denmark.
Receive News & Ratings for Orgenesis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orgenesis and related companies with MarketBeat.com's FREE daily email newsletter.
